Vaccine Technology Vaccine Development Reproductive Technology Blood Testing Health Innovations Gene Therapy Stem Cell Therapy Regenerative Medicine Diagnostic Tools Imaging Technology Diagnostics Organ Replacement Gene Editing Technology Targeted Therapies Health Improvement Tissue Engineering Drug Delivery Systems Research Methods Gene Editing Organ Printing Organ Transplants Transplant Technology Cancer Screening Implant Technology Therapeutics Diagnostic Technology Extracellular Matrix Cancer Treatment Technology Regenerative Medicine Technology Gel Formation Drug Development Infection Prevention Artificial Intelligence Drug Innovation Antimalarial Compounds Diagnostic Innovations Targeted Therapy mRNA Technology
The one-time in vivo candidate TSRA-196 targets correction of SERPINA1 mutations, with Tessera planning an FDA filing by year-end.
